Behandeling met het Nanoknife® systeem bij patiënten met alvleesklierkanker die niet operatief verwijderd kan worden.
Recruiting
- Conditions
- pancreatic cancer, pancreatic adenocarcinoma, local ablative therapy, irreversible electroporationalvleesklierkanker, pancreascarcinoom, lokale ablatietherapie, irreversibele electroporatie
- Registration Number
- NL-OMON20237
- Lead Sponsor
- AMC Amsterdam
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 106
Inclusion Criteria
•Age 18 years or older
•Capable of providing written and oral informed consent
Exclusion Criteria
•Resectable pancreatic cancer during explorative laparotomy
•Presence of metastatic disease (peritoneal, liver or other)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome is the effect of IRE on severe morbidity and mortality occurring until 90 days after IRE treatment. Severe morbidity is defined as defined as Clavien-Dindo score 3 or more.
- Secondary Outcome Measures
Name Time Method Secondary outcomes are the success rate of completing IRE procedure, duration of IRE procedure, intraprocedural complications, the impact of IRE on functional recovery, hospital stay, adverse events, need for re-interventions and readmissions and, effects on survival rates (2-year survival, median survival, progression free survival). <br>Other study parameters are baseline characteristics